U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07651748) titled 'Secretin in Ex-situ Liver Perfusion' on Jan. 26.
Brief Summary: The main objective is to assess whether the use of human synthetic secretin in a clinical (COR-)NMP procedure can restore physiological HCO3- content of the bile during ex-situ NMP.
Study Start Date: April 26, 2025
Study Type: INTERVENTIONAL
Condition:
Liver Transplantation
Intervention:
DRUG: Secretin administration during ex-situ liver machine perfusion
In at least 20 cases of sequential hypo- to normothermic machine perfusion, linked with controlled oxygenated rewarming (COR) for 60 minutes (DHOPE-COR-NMP) livers, the investigators will add 16mcg of synthetic ...